Nonetheless, in randomized phase three trials, the benefit–risk profile of PD-1 blockade plus lenalidomide and dexamethasone was unfavorable, both in newly diagnosed and relapsed and/or refractory MM patients [47,48], raising questions about future targeting of PD-1 and PD-L1 in MM [49]. Here, CD274 is linked to Miyoshi myopathy.